|
06 Feb 2020 |
Calibr’s ‘switchable’ CAR-T platform for cancer moves forward with FDA clearance of Investigational New Drug application
|
|
06 Feb 2020 |
Arrowhead Reports Interim Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3
|
|
04 Feb 2020 |
AskBio Announces First Patient Dosed in Phase 1 Trial Using AAV Gene Therapy for Congestive Heart Failure
|
|
04 Feb 2020 |
Rebiotix, a Ferring Company, Completes Enrollment for First-Ever, Pivotal Phase 3 Clinical Trial of Microbiota-based RBX2660
|
|
04 Feb 2020 |
HGF Gene Therapy Product Collategene AnGes Inc. initiated Phase 2b study in the U.S. in patients with lower limb ischemic ulcers
|
|
03 Feb 2020 |
Avacta and Daewoong Agree Collaboration and License Agreement with AffyXell Therapeutics
|
|
03 Feb 2020 |
Cardior Pharmaceuticals Demonstrates Reversal of Heart Failure with Lead Compound CDR132L
|
|
02 Feb 2020 |
Alnylam Receives Positive CHMP Opinion for GIVLAARI™ (givosiran) for the Treatment of Acute Hepatic Porphyria in Adults and Adolescents
|
|
30 Jan 2020 |
SQZ Biotech Announces First Patient Dosed in Phase 1 Trial of SQZ-PBMC-HPV for HPV+ Tumors
|
|
30 Jan 2020 |
Autolus Therapeutics Presents Encouraging Additional Data Showcasing Clinical Progress of Programmed T Cell Therapy Pipeline in Blood Cancers
|
|
30 Jan 2020 |
miRagen Therapeutics Announces Positive Data for Cobomarsen in Adult T-Cell Leukemia/lymphoma Patients With Residual Disease
|
|
30 Jan 2020 |
Rubius Therapeutics Announces First Patient Dosed in Phase 1b Trial of RTX-134 for the Treatment of Patients with Phenylketonuria
|
|
30 Jan 2020 |
Sorrento and Celularity to Initiate Emergency Allogeneic Natural Killer (NK) Cell Therapy Development for Coronavirus Infection
|
|
30 Jan 2020 |
European Medicines Agency Validates Kite’s Marketing Application for Company’s Second CAR T Cell Therapy
|
|
30 Jan 2020 |
Unum Therapeutics Provides Updates to its Phase 1 Trial of ACTR707 for HER2+ Solid Tumor Cancers
|
|
29 Jan 2020 |
Akcea and Ionis report positive topline phase 2 study results of AKCEA-ANGPTL3-LRx
|
|
29 Jan 2020 |
Seelos Therapeutics Announces Update to Parkinson’s Disease Program SLS-007
|
|
27 Jan 2020 |
TILT Biotherapeutics Signs a Licensing Deal with Biotheus, Inc for Cancer Therapy with Oncolytic Virus TILT-123
|
|
25 Jan 2020 |
Bellicum Presents New Translational Data for BPX-601 at ASCO GI Cancers Symposium
|
|
25 Jan 2020 |
Ervaxx and Cardiff University Enter Collaboration to Develop Novel T-cell and T-cell Receptor-based Immunotherapeutics Targeting Dark Antigens™
|
|
25 Jan 2020 |
Sirnaomics Advances RNAi-Based Prophylactics and Therapeutics to Battle SARI Caused by 2019-nCoV
|
|
22 Jan 2020 |
Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-L Rx
|
|
22 Jan 2020 |
Celularity Announces FDA Clearance of Landmark IND for CYNK-001, an Allogeneic, Off-the-Shelf Cryopreserved NK Cell Therapy
|
|
22 Jan 2020 |
Targovax Announces Encouraging Data in Mesothelioma Study Combining ONCOS-102 and Standard of Care Chemotherapy
|
|
22 Jan 2020 |
PDC*line Pharma raises €20 million in Series B financing round
|
